TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04719442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Healthy Families
Description: Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Building Healthy Families
Description: Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
Study: NCT05362604

Intervention type: PROCEDURE
Intervention: scheduled delivery at a tertiary center
Description: Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
Study: NCT06399835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: Enavogliflozin 0.3mg once daily
Study: NCT05897034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
Study: NCT06399835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg once daily
Study: NCT04542473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Enzyme
Description: CREON micro 5000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: Ursodiol C24H40O4 suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pancreatic Enzyme placebo
Description: Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic acid placebo
Description: Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
Study: NCT06485830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural mobilization of the lower limb
Description: Static neural mobilization techniques will be performed for the lower limb. Static procedures will consist of two sets of 10 repetitions, with one minute rest between sets. Next, dynamic neural mobilization techniques will be performed, with each exercise lasting 5 minutes per set, with one minute rest between them. Therefore, dynamic procedures will consist of 10 minutes per mobilization technique (with one minute rest between exercises).~At the end of all dynamic mobilization exercises, static mobilizations of the sciatic nerve will be performed again in the same order and with the same duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: The intervention will include a first part in which active mobilizations, active-assisted mobilizations, and active stretches will be performed, followed by activities aimed at improving physical training, mobility training, and strength training oriented towards specific tasks. After this second part, the first part will be repeated in the same order and duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center
Study: NCT04951609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will receive a single oral dose of seltorexant.
Study: NCT05408390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPD+LED
Description: Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPD+LED
Description: High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPD+HED
Description: Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPD+HED
Description: High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
Study: NCT05620966

Intervention type: DEVICE
Intervention: CGX Systems Quick-20m
Description: The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.

Intervention type: DEVICE
Intervention: CGX Systems Quick-20m
Description: The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.

Intervention type: DEVICE
Intervention: CGX Systems Quick-20m
Description: The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
Study: NCT05468034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
Study: NCT05328999

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics (Omnibiotic (R))
Description: As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
Study: NCT04807816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of berzosertib with gemcitabine
Description: Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization.
Study: NCT05432492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion, specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion, specified dose on specified days
Study: NCT05681065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TeNDER tool
Description: The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor.
Study: NCT05159518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion
Study: NCT06197789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-105
Description: Subjects will be administered with autologous fibroblasts through injection

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with Placebo through injection
Study: NCT04751318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg Test Drug Enteric Coated Granules
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg Reference Product Enteric Coated Granules
Description: Cymbalta (Eli Lilly)
Study: NCT03570814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Albendazole on Day 1
Description: Participants will receive Albendazole 400mg on study day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Albendazole on Day 1
Description: Participants will receive Albendazole 400mg on study day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Ivermectin on Day 1
Description: Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Ivermectin on Day 1
Description: Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Azithromycin on Day 1
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Azithromycin on Day 15
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
Study: NCT04555564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technicium 99 MAA infusion
Description: 4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
Study: NCT04966260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Virtual Reality
Description: This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Virtual Reality
Description: This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
Study: NCT05549830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Positioning
Description: In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals.
Study: NCT04593758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613 + Hydroxychloroquine
Description: dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg
Study: NCT04950530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
Study: NCT05488457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deuterated oxytocin (d5OT)
Description: Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
Study: NCT04770116

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auditory Stimulation
Description: The device records biosignals and precisely plays tones to enhance sleep slow waves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation
Description: The device records biosignals and precisely plays tones to enhance sleep slow waves.
Study: NCT05833438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN+AZA-5
Description: Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Study: NCT04914533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminance RED Low Level Laser Therapy Device
Description: Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
Study: NCT06355453

Intervention type: DEVICE
Intervention: Goldcrest Patch and Three Patch Coupons
Description: Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.

Intervention type: DEVICE
Intervention: Goldcrest Patch and Novii Patch
Description: Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
Study: NCT06259669

Intervention type: DRUG
Intervention: Ruxolitinib Cream
Description: Ruxolitinib Cream

Intervention type: DRUG
Intervention: Ruxolitinib Cream
Description: Ruxolitinib Cream
Study: NCT06059404

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meals + RD services only
Description: Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meals + OT services only
Description: Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meals + RD + OT services
Description: A combination of tailored registered dietitian and occupational therapy services will be provided
Study: NCT03120130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amblyomin-X
Description: Intravenous drug administration, with different doses in each cohort
Study: NCT05367791

Intervention type: OTHER
Group type: OTHER
Intervention: POSTUR
Description: Training sessions without any stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: POSTUR
Description: Training sessions without any stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: POSTUR
Description: Training sessions without any stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: POSTUR
Description: Training sessions without any stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Localised Vibration
Description: Training sessions with localized vibration

Intervention type: OTHER
Group type: OTHER
Intervention: Localised Vibration
Description: Training sessions with localized vibration

Intervention type: OTHER
Group type: OTHER
Intervention: Somatosensory Electrical Stimulation
Description: Training sessions with somatosensory electrical stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Somatosensory Electrical Stimulation
Description: Training sessions with somatosensory electrical stimulation
Study: NCT05743361

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
Study: NCT04861935

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound evaluation
Description: ultrasound evaluation of normal patients and patients who have a sacral dimple

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound evaluation
Description: ultrasound evaluation of normal patients and patients who have a sacral dimple
Study: NCT04951609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally.